Re-Stem Biotech Sponsors Guangdong Private Entrepreneurs Golf Association Invitational Tournament
By: ReStem Biotech
The annual golf tournament brings together top executives in various industries in Guangdong Province in order to promote cooperation between private entrepreneurs, share resources and promote economic development in the province.
At the tournament dinner Benno Jiao, CEO of Re-Stem, presented the Company's history as one of the leading stem cell technology firms in China and one of the first to be certified as a stem cell supplier and stem cell bank. He also explained Re-Stem's stem cell pipeline of various drugs and therapies, including its therapy RE-KneewTM for Knee Osteoarthritis (KOA), which has completed clinical trials in China and is on the market.
RE-KneewTM is an autologous human adipose-derived mesenchymal stem cell (haMPC) therapy developed to address knee osteoarthritis. The advanced proprietary process isolates and excites regenerative cells, which effects may include regeneration of cartilage and reduction of inflammation and degeneration. This therapy has successfully treated many athletes commonly affected by KOA and related knee injuries, including golfers and marathon runners.
About Osteoarthritis in China
Osteoarthritis is the second leading cause of disability and KOA is one of the most common joint diseases worldwide. In China the prevalence of symptomatic KOA was 8.1% in 2012, which is estimated to be over 100 million people suffering with KOA. Since drug-based methods to manage KOA are ineffective, many patients degenerate to the point of requiring artificial joint replacement surgery. According to the statistics of the National Cartilage Association, the total number of joint replacement cases in China is about 100,000 every year.
 Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, et al. Knee replacement. The Lancet 2012;379(9823):
 Tang, X. et al. The Prevalence of Symptomatic Knee Osteoarthritis in China: Results From the China Health and Retirement Longitudinal Study. Arthritis Rheumatol. 68, 648–653 (2016).
About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing and Ganzhou.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as "will," "may," "expects," "plans," "intends," "estimates,"